Cargando…

Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis

BACKGROUND: The objective of this study is to evaluate the efficacy and safety of different third-line treatment regimens for metastatic colorectal cancer (mCRC) through a comprehensive analysis and network meta-analysis (NMA). Additionally, the study aims to provide guidance on selecting appropriat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Loulu, Tang, Lin, Hu, Zixuan, Peng, Jieqiong, Li, Xiaoqian, Liu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552753/ https://www.ncbi.nlm.nih.gov/pubmed/37810981 http://dx.doi.org/10.3389/fonc.2023.1269203

Ejemplares similares

Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
por: Xue, Wen-Hui, et al.
Publicado: (2023)

Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis
por: Zhang, Chan, et al.
Publicado: (2023)

Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer
por: Walter, Thomas, et al.
Publicado: (2020)

Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
por: Huang, Miao, et al.
Publicado: (2021)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
por: Qin, Suyang, et al.
Publicado: (2023)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
por: Pan, Wen-Tao, et al.
Publicado: (2020)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
por: ELBassiouny, Mohamed
Publicado: (2023)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
por: Salvatore, Lisa, et al.
Publicado: (2023)

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
por: Jiang, Yanfeng, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
por: Jin, Ying, et al.
Publicado: (2022)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials
por: Hoang, Tung, et al.
Publicado: (2022)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
por: Gaulin, J., et al.
Publicado: (2009)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis
por: Wang, Changjun, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
por: Gao, Loulu, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
por: Unseld, Matthias, et al.
Publicado: (2020)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
por: Dane, Faysal, et al.
Publicado: (2020)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Wang, Lei, et al.
Publicado: (2023)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Peng, Ling, et al.
Publicado: (2021)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s60oiif92b87ioi2oijh2c05tf